Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05824000
Other study ID # COC-R6-CBM
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 7, 2022
Est. completion date August 5, 2022

Study information

Verified date May 2023
Source C.O.C. Farmaceutici S.r.l.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Allergic conjunctivitis (or ocular allergy) and dry eye disease (DED) are two major ocular surface disorders affecting millions of people. A typical clinical symptom of allergic conjunctivitis is itching which is also observed in subjects suffering from DED. Common symptoms of DED also include a foreign body sensation, dryness, irritation, burning sensation and visual disturbance. Patients with allergic conjunctivitis or moderate-to-severe DED may experience a reduced quality of life due to ocular pain, difficulty in performing daily activities, and depression. Gel-based artificial tear supplements may offer longer retention times and act as a supplement to the mucin layer. Carbomer (also known as Carbopol polymers) is awater-soluble polymeric resin that exhibit excellent viscoelastic and mucoadhesive properties when compared with other polymers. Carbomer is used in liquid or semisolid pharmaceutical, cosmetics, and ophthalmic formulations as rheology modifiers. Aqueous carbomer gels have been used for the treatment of dry eye and allergic conjunctivitis as they provide prolonged ocular residence time of conventional ophthalmic solutions. Furthermore, carbomer has shown compatibility with many active ingredients, good thermal stability, excellent organoleptic characteristics, and good patient acceptance. For these reasons, an interventional, non-comparative, single-center Post Marketing Clinical Follow-up (PMCF) study was planned to evaluate the performance and safety of "Optrex Double Action soothing and lubricating drops" for itchy and watery eyes. The objectives of the PMCF study are confirmation of the performance, collection of additional safety data regarding expected adverse events and detection of potential unexpected adverse events associated with the use of "Optrex Double Action soothing and lubricating drops" according to the Instructions for Use (IFU). Each subject, after signing the Informed Consent Form, will enter the screening and baseline phase (the 2 visits will coincide) during which baseline procedures will be completed. At baseline visit, "Optrex Double Action soothing and lubricating drops" will be prescribed to the enrolled subject. The patient will perform 2 on-site visits: V0 and V2/EOS. To monitor the safety, 1 phone contact is planned (V1) to check for potential adverse events and concomitant medications intake.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 5, 2022
Est. primary completion date August 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient Informed consent form (ICF) signed; - Male and Female Aged = 18 years at the time of the signature of the ICF; - Patients with ocular conditions typically associated with itchy and watery eyes (e.g. allergic conjunctivitis, dry eye disease); - Willing not to use other eye drops during the entire treatment period. Exclusion Criteria: - Other - different - eyes clinical conditions (e.g. glaucoma); - Suspected alcohol or drug abuse. - Known hypersensitivity or allergy to Investigational Product (IP) components; - Other clinically significant and uncontrolled pathologies that may interfere with study results (e.g. rheumatic disease, diabetes); - Participation in another investigational study; - Inability to follow all study procedures, including attending all site visits, tests and examinations; - Mental incapacity that precludes adequate understanding or cooperation.

Study Design


Intervention

Device:
Eye drops for itchy and water eyes
Ocular drops for itchy and watery eyes

Locations

Country Name City State
Italy Azienda Ospedaliera Policlinico Mater Domini - Università Magna Grecia di Catanzaro Catanzaro CZ

Sponsors (1)

Lead Sponsor Collaborator
C.O.C. Farmaceutici S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Schirmer I test: to evaluate the performance of "Optrex Double Action soothing and lubricating drops" as soothing and lubricating eye drops for itchy and watery eyes, through the Schirmer I test From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
Secondary Change in Ocular Surface Disease Index (OSDI): to evaluate the performance of "Optrex Double Action soothing and lubricating drops" used to provide relief from eye discomfort associated with itchy and watery eyes, through OSDI From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
Secondary To evaluate the safety and tolerability of "Optrex Double Action soothing and lubricating drops" through Visual Analogue Scale (VAS) - evaluation of symptoms related to dry eye disease (burning, fatigue, discomfort, redness) Visual Analogue Scale:
Minimum value = 0; Maximum value = 10; Higher scores mean a better outcome.
End of study visit (EOS/V2 = Day 30 ± 2)
Secondary To evaluate the patient satisfaction through a Rensis Likert 5 points patient satisfaction scale Rensis Likert 5 points patient satisfaction scale Minimum value: Very dissatisfied Maximum value: Vert satisfied Higher scores mean a better outcome End of study visit (EOS/V2 = Day 30 ± 2)
See also
  Status Clinical Trial Phase
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A